版本:
中国

BRIEF-Agios Pharmaceuticals says IDHIFA NDA given PDUFA action date of Aug. 30

June 6 Agios Pharmaceuticals Inc:

* Updated data from phase 1 trial of oral IDHIFA (enasidenib) demonstrate complete responses and duration of response in patients with relapsed or refractory AML and an IDH2 mutation

* Overall safety profile was consistent with previously reported data for oral IDHIFA​

* IDHIFA NDA has been given a prescription drug user fee act PDUFA action date of Aug. 30, 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐